Induced pluripotent stem cells, the workhorse of many regenerative medicine projects, start out as differentiated cells that are reprogrammed to pluripotent stem cells by exposure to a complex set of genetic cocktails. Mayo researchers now report that using the measles virus vector; they’ve trimmed that multi-vector process with four reprogramming factors down to a single “one cycle” vector process. They say the process is safe, stable, faster and usable for clinical translation. The findings appear in the journal Gene Therapy.
“If we’re going to successfully use reprogrammed stem cells to treat patients in the clinic, we need to ensure that they are safe and effective, that is, not prone to the risk of mutation and potential tumors,” says Patricia Devaux, Ph.D., Mayo Clinic molecular scientist and senior author of the article.
“The measles virus vector has long been used safely at Mayo for treating cancer, so it is very safe. Now that we’ve combined a multiple-vectors process into one, it’s efficient as well.”Previously, the four reprogramming factors – proteins OCT4, SOX2, KLF4 and cMYC – had to be introduced individually to the cells to induce them to change in the proper fashion for the desired outcome. That led to potential partially reprogrammed cells, as not all cells received the four factors required for reprogramming. The new Mayo process combines those factors within the measles virus vector so the process happens in one step and all targeted cells have the potential to reprogram. It should be noted that this measles virus is attenuated, that is all dangerous aspects of the virus have been removed, as they are in a vaccine, and the virus becomes a vector or carrier for other genetic material. The measles virus vaccine strain is often used today because it is safe, fast and targetable.
The researchers say a clinically applicable reprogramming system free from genomic modifications will go a long way to making widespread use of induced pluripotent stem cell therapies feasible. These are therapies in which an individual’s own cells are reprogrammed can then be use to work in a particular diseased organ, thus avoiding risk of cell rejection.
This article has been republished from materials provided by the Mayo Clinic. Note: material may have been edited for length and content. For further information, please contact the cited source.
Wang, Q., Vossen, A., Ikeda, Y., & Devaux, P. (2019). Measles vector as a multiple genes delivery platform facilitating iPSC reprogramming. Gene Therapy. doi:10.1038/s41434-019-0058-7